Research graph
References from Alpha particle therapy in glioblastoma: emerging biomarkers, mechanisms of response, and translational opportunities. Local targets link to admitted publications; unresolved targets remain external evidence.
CBTRUS statistical report: Primary brain and other central nervous system tumors diagnosed in the United States in 2018-2022
10.1093/neuonc/noaf194 · 2025 · External reference
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma
10.1201/9781003416197-1 · 2005 · External reference
Progression-free survival 2 as a potential surrogate for overall survival in glioblastoma: Insights from a Spanish multicentric cohort
2026 · External reference
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial
10.1016/s1470-2045(09)70025-7 · 2009 · External reference
Tumor treating fields: Narrative review of a promising treatment modality for cancer
10.21037/cco-23-82 · 2023 · External reference
Patterns and timing of recurrence after temozolomide-based chemoradiation for glioblastoma
10.1016/j.ijrobp.2009.09.018 · 2010 · External reference
Emerging role of glioma stem cells in mechanisms of therapy resistance
10.3390/cancers15133458 · 2023 · External reference
Mechanisms, microenvironments, and models: Understanding therapeutic resistance in glioblastoma
10.1016/j.ijrobp.2026.04.013 · 2026 · External reference
Intratumoral heterogeneity: Pathways to treatment resistance and relapse in human glioblastoma
10.1093/annonc/mdx169 · 2017 · External reference
The immunosuppressive microenvironment of glioblastoma: Mechanisms, clinical challenges and future directions
10.1111/imm.70087 · 2026 · External reference
Regorafenib compared with lomustine in patients with relapsed glioblastoma (REGOMA): A multicentre, open-label, randomised, controlled, phase 2 trial
10.1016/s1470-2045(18)30675-2 · 2019 · External reference
Therapy for diffuse astrocytic and oligodendroglial tumors in adults: ASCO-SNO guideline rapid recommendation update
10.1093/neuonc/noaf072 · 2025 · External reference
Pulsed-reduced dose rate (PRDR) radiotherapy for recurrent primary central nervous system Malignancies: Dosimetric and clinical results
10.3390/cancers14122946 · 2022 · External reference
Targeted alpha therapy, an emerging class of cancer agents: A review
10.1001/jamaoncol.2018.4044 · 2018 · External reference
Differential roles of DNA double strand break repair pathways in response to X-ray, proton, and alpha-particle irradiation
10.1080/09553002.2025.2590742 · 2026 · External reference
Alpha-particle emitting 213Bi-anti-EGFR immunoconjugates eradicate tumor cells independent of oxygenation
10.1371/journal.pone.0064730 · 2013 · External reference
Current landscape and future directions of targeted-alpha-therapy for glioblastoma treatment
10.7150/thno.106081 · 2025 · External reference
Radiotherapy resistance in glioblastoma: mechanistic insights and novel therapeutic approaches (review)
10.3892/ijo.2026.5907 · 2026 · External reference
Targeted alpha therapy for glioblastoma
10.3389/fmed.2022.1085245 · 2022 · External reference
Radiotherapy, immunity, and immune checkpoint inhibitors
10.1016/s1470-2045(24)00075-5 · 2024 · External reference
Diffusing alpha-emitters radiation therapy in combination with temozolomide or bevacizumab in human glioblastoma multiforme xenografts
10.3389/fonc.2022.888100 · 2022 · External reference
Stereotactic implantation of diffusing alpha-emitters radiation therapy sources in the swine brain: A potential new focal therapy for brain tumors
10.1007/s11060-024-04919-5 · 2025 · External reference
Locoregional treatment of glioblastoma with targeted alpha therapy: [ 213 Bi]Bi-DOTA-Substance P versus [ 225 Ac]Ac-DOTA-Substance P-analysis of influence parameters
10.1097/rlu.0000000000004608 · 2023 · External reference
Radiobiological effect of alpha particles. The scientific basis of targeted alpha-particle therapy
10.1016/j.nucmedbio.2025.109044 · 2025 · External reference
Diffusing alpha-emitters radiation therapy: Approximate modeling of the macroscopic alpha particle dose of a point source
10.1088/1361-6560/ab5b73 · 2020 · External reference
First measurements of radon-220 diffusion in mice tumors, towards treatment planning in diffusing alpha-emitters radiation therapy
10.1002/mp.17020 · 2024 · External reference
Diffusing alpha-emitters radiation therapy: In vivo measurements of effective diffusion and clearance rates across multiple tumor types
10.1002/mp.70052 · 2025 · External reference
Extended follow-up outcomes from pooled prospective studies evaluating efficacy of interstitial alpha radionuclide treatment for skin and head and neck cancers
10.3390/cancers16132312 · 2024 · External reference
Initial safety and tumor control results from a "first-in-human" multicenter prospective trial evaluating a novel alpha-emitting radionuclide for the treatment of locally advanced recurrent squamous cell carcinomas of the skin and head and neck
10.1016/j.ijrobp.2019.10.048 · 2020 · External reference
Feasibility, safety and efficacy of endoscopic ultrasound-guided alpha radiotherapy for advanced pancreatic cancer: A pilot study
10.1200/jco.2026.44.2_suppl.721 · 2026 · External reference
Diffusing alpha-emitters radiation therapy promotes a proimmunogenic tumor microenvironment and synergizes with programmed cell death protein 1 blockade
10.1016/j.ijrobp.2022.08.043 · 2023 · External reference
Combining alpha radiation-based brachytherapy with immunomodulators promotes complete tumor regression in mice via tumor-specific long-term immune response
10.1007/s00262-019-02418-5 · 2019 · External reference
The neurokinin-1 receptor is essential for the viability of human glioma cells: A possible target for treating glioblastoma
10.1155/2022/6291504 · 2022 · External reference
(225)Ac- and (213)Bi-substance P analogues for glioma therapy
10.1053/j.semnuclmed.2019.11.004 · 2020 · External reference
Dose escalation study of targeted alpha therapy with [(225)Ac]Ac-DOTA-substance P in recurrence glioblastoma - safety and efficacy
10.1007/s00259-021-05350-y · 2021 · External reference
Safety and efficacy of targeted alpha therapy with (213)Bi-DOTA-substance P in recurrent glioblastoma
10.1007/s00259-018-4225-7 · 2019 · External reference
Targeted alpha-radionuclide therapy of functionally critically located gliomas with 213Bi-DOTA-[Thi8,Met(O2)11]-substance P: A pilot trial
10.1007/s00259-010-1385-5 · 2010 · External reference
Prolonged survival in secondary glioblastoma following local injection of targeted alpha therapy with (213)Bi-substance P analogue
10.1007/s00259-018-4015-2 · 2018 · External reference
Low-dose temozolomide selectively increases glioblastoma's vascular permeability, tumor microenvironment penetration and the killing potential of systemic actinium-225 alpha-particle dendrimer-radioconjugates improving treatment efficacy
10.1007/s00259-025-07332-w · 2025 · External reference
In vitro evaluation of 225Ac-DOTA-substance P for targeted alpha therapy of glioblastoma multiforme
10.1111/cbdd.13199 · 2018 · External reference
Clinical experience with alpha-particle emitting 211At: treatment of recurrent brain tumor patients with 211At-labeled chimeric antitenascin monoclonal antibody 81C6
10.2967/jnumed.107.046938 · 2008 · External reference
Remodeling the vascular microenvironment of glioblastoma with alpha-particles
10.2967/jnumed.116.173559 · 2016 · External reference
Vascular targeted radioimmunotherapy for the treatment of glioblastoma
10.2967/jnumed.115.171371 · 2016 · External reference
IL13RA2 targeted alpha particle therapy against glioblastomas
10.18632/oncotarget.17792 · 2017 · External reference
Expression of interleukin-13 receptor alpha2 in glioblastoma multiforme: implications for targeted therapies
10.1158/0008-5472.can-07-1493 · 2007 · External reference
Locoregional radionuclide therapy of glioblastoma with [(211)At]At-PDA-FAPI
10.1038/s41598-025-03356-2 · 2025 · External reference
In vitro and in vivo evaluation of (211)At-labeled fibroblast activation protein inhibitor for glioma treatment
10.1016/j.bmc.2021.116600 · 2022 · External reference
Evaluation of an (211)At-labeled RGD peptide in an orthotopic glioblastoma model by targeted alpha therapy
10.1016/j.nucmedbio.2025.109572 · 2025 · External reference
Brain intratumoural astatine-211 radiotherapy targeting syndecan-1 leads to durable glioblastoma remission and immune memory in female mice
10.1016/j.ebiom.2024.105202 · 2024 · External reference
Clustered DNA double-strand breaks: Biological effects and relevance to cancer radiotherapy
10.3390/genes11010099 · 2020 · External reference
A comprehensive review of sensors of radiation-induced damage, radiation-induced proximal events, and cell death
10.1111/imr.13409 · 2025 · External reference
In vitro evaluation of combined temozolomide and radiotherapy using X rays and high-linear energy transfer radiation for glioblastoma
10.1667/rr2803.1 · 2012 · External reference
Participation of DNA-PKcs in DSB repair after exposure to high- and low-LET radiation
10.1667/rr2071.1 · 2010 · External reference
Expression levels of RAD51 inversely correlate with survival of glioblastoma patients
10.3390/cancers13215358 · 2021 · External reference
Selective inhibition of parallel DNA damage response pathways optimizes radiosensitization of glioblastoma stem-like cells
10.1158/0008-5472.can-14-3790 · 2015 · External reference
RAD51 is a selective DNA repair target to radiosensitize glioma stem cells
10.1016/j.stemcr.2016.12.005 · 2017 · External reference
Glioma stem cells and their microenvironments: Providers of challenging therapeutic targets
10.1155/2016/5728438 · 2016 · External reference
High linear-energy-transfer radiation can overcome radioresistance of glioma stem-like cells to low linear-energy-transfer radiation
10.1093/jrr/rrt095 · 2014 · External reference
Antitumor immunity induced after alpha irradiation
10.1016/j.neo.2014.04.002 · 2014 · External reference
Targeted alpha particle therapy remodels the tumor microenvironment and improves efficacy of immunotherapy
10.1016/j.ijrobp.2021.10.013 · 2022 · External reference
MHC-I-driven antitumor immunity counterbalances low absorbed doses of radiopharmaceutical therapy
10.2967/jnumed.124.268857 · 2025 · External reference
Immunomodulatory effects of targeted radionuclide therapy
2023 · External reference
The effects of clinically relevant radionuclides on the activation of an IFN1 response correlate with radionuclide half-life and linear energy transfer and influence radiopharmaceutical antitumor efficacy
10.1158/2326-6066.cir-24-1191 · 2025 · External reference
Immunomodulatory effects of alpha vs beta radiopharmaceutical therapy in murine prostate cancer
10.3389/fimmu.2025.1563387 · 2025 · External reference
Progress in molecular markers associated with radiotherapy efficacy in glioma
10.3389/fonc.2026.1734404 · 2026 · External reference
Glioma stem cells promote radioresistance by preferential activation of the DNA damage response
10.1038/nature05236 · 2006 · External reference
Constraints, cumulative doses and toxicity outcomes in glioma reirradiation: a systematic review and radiobiological comparison from the reirradiation collaborative group (ReCog)
10.1016/j.ijrobp.2026.03.004 · 2026 · External reference
Dose escalation with intraoperative radiotherapy in newly diagnosed glioblastoma (INTRAGO-II): an open-label, multicentre, randomised, controlled, phase 3 trial
10.1016/s1470-2045(26)00235-4 · 2026 · External reference
Prognostic implications of the DNA damage response pathway in glioblastoma
2011 · External reference
Increased sensitivity to ionizing radiation by targeting the homologous recombination pathway in glioma initiating cells
10.1016/j.molonc.2014.06.012 · 2014 · External reference
Aberrant ATM signaling and homology-directed DNA repair as a vulnerability of p53-mutant GBM to AZD1390-mediated radiosensitization
10.1126/scitranslmed.adj5962 · 2024 · External reference
Primary glioblastoma cultures: can profiling of stem cell markers predict radiotherapy sensitivity
10.1111/jnc.12802 · 2014 · External reference
Expression of CD133 and CD44 in glioblastoma stem cells correlates with cell proliferation, phenotype stability and intra-tumor heterogeneity
10.1371/journal.pone.0172791 · 2017 · External reference
Targeted alpha-particle radiotherapy and immune checkpoint inhibitors induces cooperative inhibition on tumor growth of Malignant melanoma
10.3390/cancers13153676 · 2021 · External reference
STING-dependent cytosolic DNA sensing promotes radiation-induced type I interferon-dependent antitumor immunity in immunogenic tumors
10.1016/j.immuni.2014.10.019 · 2014 · External reference
Clinical predictors of pseudoprogression in glioblastoma: a retrospective cohort analysis
10.1007/s11060-025-05299-0 · 2025 · External reference
Cerebrospinal fluid ctDNA as a diagnostic and prognostic tool in gliomas: a systematic review and meta-analysis
10.3389/fonc.2025.1714287 · 2025 · External reference
Explainable, modality-adaptive radiomics for MGMT methylation prediction in high-grade glioma: a decision-curve analysis study
10.3389/fonc.2025.1731258 · 2026 · External reference
Explainable radiomics with probability calibration for postoperative glioblastoma surveillance
10.1016/j.ejrai.2026.100074 · 2026 · External reference
Multimodal artificial intelligence in glioma management: integrating neuroimaging and hematologic biomarkers for precision oncology
10.3389/fonc.2026.1812518 · 2026 · External reference
Intratumoral 224Ra-loaded wires spread alpha-emitters inside solid human tumors in athymic mice achieving tumor control
2012 · External reference
Feasibility and safety of diffusing alpha-emitter radiation therapy for recurrent or unresectable skin cancers
2023 · External reference
Unveiling the enigma of the blood-brain barrier in glioblastoma: current advances from preclinical and clinical studies
10.1097/cco.0000000000000990 · 2023 · External reference
Effect of microdistribution of alpha and beta-emitters in targeted radionuclide therapies on delivered absorbed dose in a GATE model of bone marrow
10.1088/1361-6560/abd3ef · 2021 · External reference
Optimization processes of clinical chelation-based radiopharmaceuticals for pathway-directed targeted radionuclide therapy in oncology
10.3390/pharmaceutics16111458 · 2024 · External reference
